article thumbnail

AC Immune claims half a win for tau drug in Alzheimer’s trial

pharmaphorum

Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another. Roche’s Genentech unit bought into the programme in 2012 and amended it three years later.

article thumbnail

GSK, Verily-backed Galvani starts trials of bioelectronic arthritis therapy

pharmaphorum

Lab studies have suggested that this type of stimulation can alter immune cells made in the spleen switching them from a pro-inflammation to an anti-inflammation state. Galvani is using its device to stimulate the splenic nerve, which sends signals to the spleen.

Immunity 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23. was powered by the advent of immune-checkpoint inhibitors, added Chalk.

Immunity 105
article thumbnail

The role of data science and text mining in the search for new therapies

pharmaphorum

“Text mining was also able to highlight new insights into the mechanisms of pancreatic cancer’s immune evasion, which refers to cancer cells’ ability to evade an immune response” . This was only discovered in 2012 and is a currently active area of research within pancreatic cancer.

Immunity 105
article thumbnail

AI drug discovery biotech AbCellera eyes record IPO

pharmaphorum

AbCellera is a specialist in applying artificial intelligence to drug discovery, specifically to sift through immune system data to find antibodies that can be developed as drugs. AbCellera was founded in 2012 and posted $28 million in revenue for the 12 months ending 30 September.

Immunity 111
article thumbnail

New Legislation Would Cut Off Access To The Courts And Immunize FDA Actions From Timely Judicial Review

FDA Law Blog: Biosimilars

Senate Committee on Health, Education, Labor and Pensions (“Senate HELP”) is scheduled to take up legislation that could significantly limit access to the courts and immunize critical FDA decisions from timely judicial review. 112-144 (2012). Importantly, because FDA has sovereign immunity from damages claims, sponsors trapped in S.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 4 BsMAb amivantamab was designed to enhance adherence of tumour cells to macrophages and natural killer cells, to improve immune-cell mediated killing of cancer cells. 2012; 23(8): 6 – 9.